Lab to Marketplace: Tools for Biomedical and Behavioral Research (SBIR [R43/R44])
The summary for the Lab to Marketplace: Tools for Biomedical and Behavioral Research (SBIR [R43/R44]) grant is detailed below.
This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants.
Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact.
If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.
Lab to Marketplace: Tools for Biomedical and Behavioral Research (SBIR [R43/R44]): -Purpose. This Funding Opportunity Announcement (FOA) encourages the translation of technologies for biomedical or behavioral research from academic and other non-small business research sectors to the marketplace. Small Business Concerns (SBCs) are encouraged to submit Small Business Innovation Research (SBIR) grant applications that propose to further develop, make more robust, and make more user-friendly such technologies in preparation for commercial dissemination. It is expected that this activity will require partnerships and close collaboration between the original developers of these technologies and SBCs, which may be accomplished in any of a number of ways, including the use of multiple principle investigators. -Mechanism of Support. This FOA will utilize the SBIR (R43/R44) grant mechanisms for Phase I, Phase II, and Fast-Track applications. This FOA runs in parallel with an FOA affiliated with the NIH Blueprint for Neuroscience Research, PA-08-071, Lab to Marketplace Tools for Brain and Behavioral Research. -Funds Available and Anticipated Number of Awards. For this FOA, Budgets up to $350,000 total costs per year and time periods up to 2 years for Phase I may be requested. Budgets up to $600,000 total costs per year and up to 3 years may be requested for Phase II. Phase II competing renewal budgets must be submitted in accordance with participating IC-specific budget limitations described in the SBIR Omnibus Solicitation Program Descriptions and Research Topics. Awards issued under this FOA are contingent upon the availability of funds and the submission of a sufficient number of meritorious applications.
| Federal Grant Title: | Lab to Marketplace: Tools for Biomedical and Behavioral Research (SBIR [R43/R44]) |
| Federal Agency Name: | National Institutes of Health |
| Grant Categories: | Education Food and Nutrition Health |
| Type of Opportunity: | Discretionary |
| Funding Opportunity Number: | PA-08-114 |
| Type of Funding: | Grant |
| CFDA Numbers: | 93.172 |
| CFDA Descriptions: | Human Genome Research |
| Current Application Deadline: | May 07, 2011 |
| Original Application Deadline: | May 07, 2011 |
| Posted Date: | Apr 09, 2008 |
| Creation Date: | Jan 26, 2009 |
| Archive Date: | Jun 07, 2011 |
| Total Program Funding: | |
| Maximum Federal Grant Award: | |
| Minimum Federal Grant Award: | |
| Expected Number of Awards: | |
| Cost Sharing or Matching: | No |
- Applicants Eligible for this Grant
- Small businesses
- Link to Full Grant Announcement
- Information not provided
- Grant Announcement Contact
- NIH OER [email protected]
If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster [[email protected]] - Similar Government Grants
- • Genomic Variant Interactions With Other Variants Or The Environment (UM1 Clinical Trials N...
- • Computational Modeling and Analysis of the Impact of Genomic Variation on Function (UM1, C...
- • Systematic Characterization of Genomic Variation to Assess Effects of Individual Variants ...
- • IGVF Data and Coordinating Center (U24 Clinical trials Not Allowed)
- • GREGoRi Innovation Projects (U01 Clinical Trial Optional)
- • Near-Term Technology Development for Genome Sequencing - SBIR (R43/R44)
- • Near-Term Technology Development for Genome Sequencing - STTR (R41/R42)
- • Revolutionary Genome Sequencing Technologies - The $1000 Genome - SBIR (R43/R44)
- More Grants from the National Institutes of Health
- • Advancing Real-World Effectiveness Evidence for Rapid-Acting Psychotropic Interventional D...
- • Systems Biology of Infection and Inflammation in Chronic Diseases (U19 Clinical Trial Not ...
- • NCI Research Specialist (Clinician Scientist) Award (R50 Clinical Trial Not Allowed)
- • Genomic and Biologic Therapies for ADRD (U01 Clinical Trial Optional)
- • Assay Validation of High Quality Markers for Clinical Studies in Cancer (UH2/UH3 Clinical ...
